JP2013522237A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522237A5 JP2013522237A5 JP2012557285A JP2012557285A JP2013522237A5 JP 2013522237 A5 JP2013522237 A5 JP 2013522237A5 JP 2012557285 A JP2012557285 A JP 2012557285A JP 2012557285 A JP2012557285 A JP 2012557285A JP 2013522237 A5 JP2013522237 A5 JP 2013522237A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- seq
- antibody
- sequence
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 21
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000005461 Canertinib Substances 0.000 claims 1
- 230000004544 DNA amplification Effects 0.000 claims 1
- 101150054472 HER2 gene Proteins 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102100025803 Progesterone receptor Human genes 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229950002826 canertinib Drugs 0.000 claims 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 108700020302 erbB-2 Genes Proteins 0.000 claims 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31289510P | 2010-03-11 | 2010-03-11 | |
| US61/312,895 | 2010-03-11 | ||
| PCT/US2011/028129 WO2011112953A2 (en) | 2010-03-11 | 2011-03-11 | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016045111A Division JP6185102B2 (ja) | 2010-03-11 | 2016-03-09 | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522237A JP2013522237A (ja) | 2013-06-13 |
| JP2013522237A5 true JP2013522237A5 (cg-RX-API-DMAC7.html) | 2014-04-24 |
Family
ID=44513103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557285A Pending JP2013522237A (ja) | 2010-03-11 | 2011-03-11 | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
| JP2016045111A Expired - Fee Related JP6185102B2 (ja) | 2010-03-11 | 2016-03-09 | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016045111A Expired - Fee Related JP6185102B2 (ja) | 2010-03-11 | 2016-03-09 | トリプルネガティブおよび基底様乳癌の治療におけるｅｒｂｂ３阻害剤の使用 |
Country Status (20)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| US9855291B2 (en) | 2008-11-03 | 2018-01-02 | Adc Therapeutics Sa | Anti-kidney associated antigen 1 (KAAG1) antibodies |
| NZ600262A (en) | 2009-12-22 | 2013-06-28 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| SG183532A1 (en) * | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| PH12013500333A1 (en) | 2010-08-20 | 2013-04-22 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| BR112013022882A2 (pt) * | 2011-03-11 | 2016-12-20 | Merrimack Pharmaceuticals Inc | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários |
| SMT201900505T1 (it) | 2011-03-31 | 2019-11-13 | Adc Therapeutics Sa | Anticorpi contro l'antigene 1 associato ai reni e loro frammenti leganti l'antigene |
| JP2014527035A (ja) * | 2011-06-30 | 2014-10-09 | メリマック ファーマシューティカルズ インコーポレーティッド | 婦人科悪性腫瘍を治療するためのパクリタキセルとの組み合わせの抗ＥｒｂＢ３抗体 |
| HK1200468A1 (en) | 2011-09-30 | 2015-08-07 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| CA2851314A1 (en) * | 2011-10-06 | 2013-04-11 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-erbb3 antibodies |
| EP2766045B1 (en) * | 2011-10-13 | 2016-12-07 | The Regents of The University of California | Treatment of breast cancer with companion diagnostic |
| WO2013078191A1 (en) | 2011-11-23 | 2013-05-30 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| ES2758433T3 (es) * | 2011-12-05 | 2020-05-05 | Novartis Ag | Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3) |
| CA2857400A1 (en) * | 2012-01-09 | 2013-07-18 | Alethia Biotherapeutics Inc. | Anti-kaag1 antibodies or antigen binding fragment thereof for treatment of triple negative breast cancer |
| US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
| EP3584259A1 (en) * | 2012-10-24 | 2019-12-25 | Yeda Research and Development Co., Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
| US9566334B2 (en) | 2012-12-07 | 2017-02-14 | The General Hospital Corporation | Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015148971A2 (en) | 2014-03-27 | 2015-10-01 | Research Foundation Of The City University Of New York | Method for detecting or treating triple negative breast cancer |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| EP3283068A1 (en) | 2015-04-17 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
| US9795624B2 (en) | 2015-05-04 | 2017-10-24 | Research Foundation Of The City University Of New York | Cationic polymers as co-drugs for chemotherapeutic agents |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CA2989400A1 (en) * | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
| CN105375955B (zh) * | 2015-10-26 | 2018-07-17 | 西安电子科技大学 | 一种信能同传中继网络中的协作传输方法 |
| KR101746152B1 (ko) * | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도 |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| CA3011949A1 (en) | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
| KR101923641B1 (ko) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| US11260132B2 (en) | 2017-03-16 | 2022-03-01 | Children's Medical Center Corporation | Engineered liposomes as cancer-targeted therapeutics |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| JP2022512038A (ja) * | 2018-10-21 | 2022-02-01 | エスエルエスジー リミテッド エルエルシー | トリプルネガティブ乳癌治療のための併用免疫療法 |
| AR117994A1 (es) * | 2019-02-05 | 2021-09-08 | Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet | Métodos para tratar cáncer de mama triple negativo utilizando una proteína mutante de erbb-2 humana |
| CN112755173B (zh) * | 2020-12-31 | 2022-01-07 | 深圳市科达顺生物技术有限公司 | 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法 |
| CN117412766A (zh) * | 2021-03-11 | 2024-01-16 | 艾利维申肿瘤学公司 | 抗erbb3(her3)单克隆抗体治疗与神经调节蛋白1(nrg1)基因融合相关肿瘤的剂量和给药 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5344760A (en) | 1991-06-03 | 1994-09-06 | Ciba Corning Diagnostics Corp. | Method of cancer detection |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6983227B1 (en) | 1995-01-17 | 2006-01-03 | Intertech Ventures, Ltd. | Virtual models of complex systems |
| ATE483733T1 (de) | 1995-06-14 | 2010-10-15 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
| PT896586E (pt) | 1996-03-27 | 2007-01-31 | Genentech Inc | Anticorpos de erbb3 |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| CN1202247C (zh) | 1996-07-12 | 2005-05-18 | 基因技术股份有限公司 | 嵌合异源多亚基粘附素 |
| US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
| US20020002276A1 (en) | 1997-02-10 | 2002-01-03 | Genentech, Inc. | Chimeric heteromultimer adhesins |
| US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
| GB2336695A (en) | 1998-04-20 | 1999-10-27 | Teamware Group Oy | Modelling a work process |
| AU4079999A (en) | 1998-05-15 | 1999-12-06 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP2110138A1 (en) | 1999-08-27 | 2009-10-21 | Genentech, Inc. | Dosages for treatment of anti-erbB2 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| EP1285092A4 (en) | 2000-04-14 | 2003-07-16 | Metabolon Inc | METHOD FOR DISCOVERY OF MEDICINES, DISEASE TREATMENT AND DIAGNOSIS USE THE METABOLOMICS |
| AU2001264696B2 (en) | 2000-05-19 | 2007-01-04 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy |
| US20020119148A1 (en) | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
| US6871171B1 (en) | 2000-10-19 | 2005-03-22 | Optimata Ltd. | System and methods for optimized drug delivery and progression of diseased and normal cells |
| EP1228766A1 (en) | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
| ATE446317T1 (de) * | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
| US7638302B2 (en) | 2001-05-31 | 2009-12-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7125680B2 (en) | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
| EP1421113A4 (en) | 2001-08-03 | 2005-04-13 | Commw Scient Ind Res Org | SCREENING BASED ON THE CRYSTAL STRUCTURE OF THE EGF RECEPTOR |
| US7662374B2 (en) | 2001-08-03 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbB family members and methods of use thereof |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| KR20050038578A (ko) | 2001-10-19 | 2005-04-27 | 파르마 마르, 에스.에이. | 항종양성 화합물의 암치료에 있어서의 향상된 용도 |
| US7415359B2 (en) | 2001-11-02 | 2008-08-19 | Gene Network Sciences, Inc. | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents |
| CA2480099C (en) | 2002-03-26 | 2019-01-08 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| US20040132097A1 (en) | 2002-06-19 | 2004-07-08 | Bacus Sarah S. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| JP4609930B2 (ja) | 2002-12-11 | 2011-01-12 | ベンタナ・メディカル・システムズ・インコーポレーテッド | Ｈｅｒ−２指向性治療に対する応答を予測する方法 |
| EP1613732A4 (en) | 2003-04-01 | 2012-03-14 | Monogram Biosciences Inc | INTRA-CELLULAR COMPLEXES AS BIOMARKERS |
| WO2005014618A2 (en) | 2003-08-08 | 2005-02-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
| WO2005017493A2 (en) | 2003-08-15 | 2005-02-24 | Smithkline Beecham Corporation | Biomarkers in cancer |
| US8554486B2 (en) | 2004-02-20 | 2013-10-08 | The Mathworks, Inc. | Method, computer program product, and apparatus for selective memory restoration of a simulation |
| DK2439285T3 (da) | 2004-03-31 | 2019-07-29 | Massachusetts Gen Hospital | Fremgangsmåde til at bestemme reaktivitet af cancer på behandlinger målrettet mod epidermal vækstfaktor-receptor |
| CN1997382A (zh) | 2004-05-05 | 2007-07-11 | 梅里麦克制药股份有限公司 | 调节生物活性的双特异性结合剂 |
| WO2005117553A2 (en) | 2004-05-27 | 2005-12-15 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| WO2005121380A1 (en) | 2004-06-04 | 2005-12-22 | Smithkline Beecham Corporation | Predictive biomarkers in cancer therapy |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| WO2006017859A2 (en) | 2004-08-06 | 2006-02-16 | Genentech, Inc. | Assays and methods using biomarkers |
| CA2576886A1 (en) | 2004-08-12 | 2006-02-23 | Dyax Corp. | Tie complex binding proteins |
| US20060136139A1 (en) | 2004-10-12 | 2006-06-22 | Elcock Adrian H | Rapid computational identification of targets |
| US20080254497A1 (en) | 2004-10-15 | 2008-10-16 | Monogram Biosciences, Inc. | Response Predictors for Erbb Pathway-Specific Drugs |
| JP2008523073A (ja) | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| WO2006091209A2 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| TW200642695A (en) | 2005-03-08 | 2006-12-16 | Genentech Inc | Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs) |
| US20090061422A1 (en) | 2005-04-19 | 2009-03-05 | Linke Steven P | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| EP1913160A2 (en) | 2005-07-29 | 2008-04-23 | Bayer Healthcare LLC | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| WO2007041502A2 (en) | 2005-09-30 | 2007-04-12 | Monogram Biosciences | Methods for determining responsiveness to cancer therapy |
| EP1931798A1 (en) | 2005-10-05 | 2008-06-18 | AstraZeneca UK Limited | Method to predict or monitor the response of a patient to an erbb receptor drug |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7908091B2 (en) | 2006-03-17 | 2011-03-15 | Prometheus Laboratories Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| WO2007115571A2 (en) | 2006-04-07 | 2007-10-18 | Enkam Pharmaceuticals A/S | Erbb receptor-derived peptide fragments |
| ES2394224T3 (es) | 2006-05-05 | 2013-01-23 | Yale University | Uso de perfiles de localización subcelular como indicadores de prognóstico o predictivos |
| CA2657324A1 (en) | 2006-07-13 | 2008-01-17 | Yale University | Methods for making cancer prognoses based on subcellular localization of biomarkers |
| EP2062597A4 (en) * | 2006-09-15 | 2010-03-03 | Univ Tokai | PREVENTIVE OR CLEANING AGENT FOR ER-NEGATIVE AND HER2-NEGATIVE MAMMARY CARCINOMA AND INVESTIGATION METHOD THEREFOR |
| EP2094870A4 (en) | 2006-11-03 | 2010-05-05 | Univ Texas | BIFUNCTIONAL PREDICTORS OF SENSITIVITY AND RESISTANCE TO CANCER THERAPY |
| EP2518508A1 (en) | 2006-11-28 | 2012-10-31 | U3 Pharma GmbH | Activated HER3 as a marker for predicting therapeutic efficacy |
| US7825127B2 (en) | 2006-12-28 | 2010-11-02 | Takeda Pharmaceutical Company, Limited | Method for treating cancer |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
| AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| BRPI0811156A2 (pt) | 2007-05-11 | 2019-09-24 | Enzon Pharmaceuticals Inc | compostos antagonistas de rna para a modulação de her3 |
| US20090054051A1 (en) | 2007-08-22 | 2009-02-26 | James Cavallo | Attachable Headset for Portable Device |
| EP2860260A1 (en) | 2008-04-11 | 2015-04-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| AU2009281721A1 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| CA2771744A1 (en) | 2009-08-21 | 2011-02-24 | Merrimack Pharmaceuticals, Inc. | Antibodies against the ectodomain of erbb3 and uses thereof |
| WO2011047180A1 (en) | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| WO2011139681A1 (en) | 2010-04-26 | 2011-11-10 | Merrimack Pharmaceuticals | Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug |
| US9011863B2 (en) | 2010-07-09 | 2015-04-21 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
| FR2963868B1 (fr) | 2010-08-11 | 2012-09-28 | Valeo Systemes Thermiques | Echangeur de chaleur comprenant un element chauffant serigraphie |
| CA2819554A1 (en) | 2010-12-10 | 2012-06-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates |
| US20140056898A1 (en) | 2011-02-24 | 2014-02-27 | Bo Zhang | Combination therapies comprising anti-erbb3 agents |
| BR112013022882A2 (pt) * | 2011-03-11 | 2016-12-20 | Merrimack Pharmaceuticals Inc | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários |
| US20150231238A1 (en) | 2011-03-15 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
| HRP20170713T1 (hr) | 2011-04-19 | 2017-07-14 | Merrimack Pharmaceuticals, Inc. | Bispecifično anti-igf-1r i anti-erbb3 antitijelo |
| US20140234317A1 (en) | 2011-05-06 | 2014-08-21 | Merrimack Pharmaceuticals, Inc. | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents |
| AU2012273361A1 (en) | 2011-06-24 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-ErbB3 antibodies in combination with paclitaxel |
| JP2014527035A (ja) | 2011-06-30 | 2014-10-09 | メリマック ファーマシューティカルズ インコーポレーティッド | 婦人科悪性腫瘍を治療するためのパクリタキセルとの組み合わせの抗ＥｒｂＢ３抗体 |
| AU2012294326A1 (en) * | 2011-08-10 | 2013-03-21 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy |
| US20150231219A1 (en) | 2012-04-02 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies |
| WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| CA2975829A1 (en) | 2014-02-20 | 2015-09-03 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith |
-
2011
- 2011-03-11 SG SG2012063905A patent/SG183532A1/en unknown
- 2011-03-11 PT PT117301127T patent/PT2544680E/pt unknown
- 2011-03-11 AU AU2011224186A patent/AU2011224186C1/en not_active Ceased
- 2011-03-11 EP EP20140196121 patent/EP2859893A1/en not_active Ceased
- 2011-03-11 US US13/583,949 patent/US8895001B2/en not_active Expired - Fee Related
- 2011-03-11 KR KR1020127025753A patent/KR101798679B1/ko not_active Expired - Fee Related
- 2011-03-11 DK DK11730112T patent/DK2544680T3/en active
- 2011-03-11 JP JP2012557285A patent/JP2013522237A/ja active Pending
- 2011-03-11 EP EP11730112.7A patent/EP2544680B1/en not_active Revoked
- 2011-03-11 WO PCT/US2011/028129 patent/WO2011112953A2/en not_active Ceased
- 2011-03-11 NZ NZ602084A patent/NZ602084A/en not_active IP Right Cessation
- 2011-03-11 MX MX2012010226A patent/MX344355B/es active IP Right Grant
- 2011-03-11 CA CA2792327A patent/CA2792327C/en not_active Expired - Fee Related
- 2011-03-11 ES ES11730112.7T patent/ES2535503T3/es active Active
- 2011-03-11 EA EA201201186A patent/EA201201186A1/ru unknown
- 2011-03-11 CN CN201180013330.9A patent/CN102858335B/zh not_active Expired - Fee Related
- 2011-03-11 BR BR112012022802A patent/BR112012022802A2/pt not_active IP Right Cessation
- 2011-03-11 PL PL11730112T patent/PL2544680T3/pl unknown
- 2011-11-03 UA UAA201210790A patent/UA111149C2/uk unknown
-
2012
- 2012-08-27 ZA ZA2012/06425A patent/ZA201206425B/en unknown
- 2012-08-30 IL IL221693A patent/IL221693A/en not_active IP Right Cessation
-
2014
- 2014-10-20 US US14/518,900 patent/US9518130B2/en not_active Expired - Fee Related
-
2016
- 2016-03-09 JP JP2016045111A patent/JP6185102B2/ja not_active Expired - Fee Related
- 2016-11-08 US US15/346,439 patent/US20170291957A1/en not_active Abandoned
-
2018
- 2018-05-31 US US15/994,393 patent/US20190119401A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522237A5 (cg-RX-API-DMAC7.html) | ||
| JP2016166203A5 (cg-RX-API-DMAC7.html) | ||
| JP2014509593A5 (cg-RX-API-DMAC7.html) | ||
| CN102812045B (zh) | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 | |
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| TWI309167B (en) | Combination treatment for non-hematologic malignancies | |
| JP6967853B2 (ja) | ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体 | |
| JP2020099324A5 (cg-RX-API-DMAC7.html) | ||
| JP2015517300A5 (cg-RX-API-DMAC7.html) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2008500815A5 (cg-RX-API-DMAC7.html) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| JP2013506622A5 (cg-RX-API-DMAC7.html) | ||
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2013537546A5 (cg-RX-API-DMAC7.html) | ||
| JP2017514461A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500828A5 (cg-RX-API-DMAC7.html) | ||
| ME02637B (me) | Antitela za receptor 3 faktora rasta epiderma (her3) | |
| Ko et al. | Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer | |
| JP2013529183A5 (cg-RX-API-DMAC7.html) | ||
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| JP2015512877A5 (cg-RX-API-DMAC7.html) | ||
| JP2017534574A (ja) | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 | |
| TW202300527A (zh) | 使用ｇｒｅｍ１拮抗劑治療疾病的方法 |